Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53 +/7 mutation signi®cantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ERa and p16 negative. Translocations involving p53 were also identi®ed which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or girradiation, suggesting that these methods would be eective in treatment of this disease. Oncogene (2001) 20, 7514 ± 7523.
Introduction
Breast cancer is the second leading cause of cancer mortality in women (reviewed in Alberg and Helzlsouer, 1997; Brody and Biesecker, 1998; Paterson, 1998) . In families with an inherited predisposition to breast cancer, about 50% carry BRCA1 mutations. Mutations in BRCA1 also account for over 90% of cases with a family history of breast and ovarian cancers. However, mutations in BRCA1 are rarely identi®ed in sporadic cases (Easton, 1997; Futreal et al., 1994; Xu and Solomon, 1996) . This may suggest dierent pathogenic mechanisms between BRCA1 associated breast tumors and sporadic forms of breast cancer. Therefore, understanding the molecular/genetic events associated with BRCA1 tumorigenesis is of vital importance.
BRCA1 is known to associate with a number of proteins that have roles in multiple cellular processes (Deng and Brodie, 2000) . A current hypothesis is that BRCA1 functions as a`caretaker' that is responsible for maintaining genomic integrity (Kinzler and Vogelstein, 1997) . Studies have demonstrated that BRCA1 loss leads to defective DNA damage repair, abnormal centrosome duplication, G2-M cell cycle checkpoint defect, growth retardation, increased apoptosis, genetic instability, and tumorigenesis (reviewed in Deng and Brodie, 2000; Deng and Scott, 2000) . These pleiotrophic eects are manifested through BRCA1 and its interactions with tumor suppressor genes and oncogenes (Aprelikova et al., 1999; Chen et al., 1998; Cortez et al., 1999; Gatei et al., 2001; O'Brien et al., 1999; Wang et al., 1998; Wu et al., 1996) , DNA damage repair proteins (Scully et al., 1997a,b; Zhong et al., 1999) , cell cycle regulators (Runer et al., 1999; Wang et al., 1997) , ubiquitin hydrolases (Jensen et al., 1998) , and transcriptional activators and repressors (Yu et al., 1998) .
Tumor progression is a multi-step process involving cellular changes such as activation of oncogenes and/or the inactivation of tumor suppressor genes. In sporadic forms of breast cancer, a number of ampli®ed or deleted chromosome regions have been identi®ed using techniques, which test for allelic imbalance (Bieche et al., 1999; Bonsing et al., 2000; Orsetti et al., 1999; Osborne and Hamshere, 2000; Rodriguez et al., 2000; Sta et al., 2000) . In high-grade breast cancer, chromosome regions that are ampli®ed leading to protein overexpression, often include genes coding ErbB2, c-Myc and Cyclin D1 (Brison, 1993) . Recently, these genes have been shown to associate directly or indirectly with BRCA1 (Deng and Brodie, 2000; Wang et al., 2000) . This gene ampli®cation leading to elevated ErbB2 expression has been identi®ed in 30 ± 40% of human breast cancers and is associated with a poor prognosis (Slamon et al., 1987) . Allelic imbalance of chromosome 11q13 has been identi®ed in 20% of mammary carcinomas and half of the cases show Cyclin D1 overexpression (Barnes and Gillett, 1998) . Lastly, genetic ampli®cation of genomic regions containing c-Myc is frequently identi®ed in a variety of human tumors (Bieche and Lidereau, 1995) . In addition to oncogene ampli®cation in breast cancer, a variety of proteins are currently under investigation as prognostic indicators in breast cancer. These include the estrogen receptor-alpha (ERa) (Walker, 1999) and proteins responsible for the regulation of the cell cycle such as p53 and p27 (Barbareschi et al., 2000; MildeLangosch et al., 2000) .
To gain insight into inherited forms of breast cancer, we recently generated a mouse model with conditional disruption of Brca1 in mammary epithelial cells (Xu et al., 1999a) . The mammary tumors generated in these mice occur at a low frequency after long latency indicating that other factors are required for mammary tumorigenesis. In an attempt to further characterize tumors generated in Brca1 conditional knockout mice and to identify other genetic alterations associated with Brca1 tumorigenesis, we used a candidate gene approach with markers associated with mammary tumor formation on primary tumors and cell lines from these mice. We identi®ed increased expression of ErbB2, c-Myc, Cyclin D1, and p27 and decreased expression of p16 and ERa, suggesting roles for these proteins in Brca1-associated tumorigenesis.
Results

Brca1 conditional knockout mice develop mammary tumors in a stochastic fashion
We have previously demonstrated that Brca1 conditional knockout mice develop mammary tumors that are accelerated in a p53 +/7 background (Xu et al., 1999a) . Because only a small number of mice were used in that study, we failed to provide a tumorigenesis pro®le associated with the Brca1 mutation. Therefore, we were interested in analysing and characterizing additional mice to gain further insight into the mammary tumor phenotype of Brca1 conditional mice. We generated mice that carried either two Brca1 conditional alleles (Brca1 Co/Co ) or one conditional and one knock out Brca1 allele (Brca1 Ko/Co ) driven by WAP or MMTV-Cre, generating mice with the genotypes of Brca1
Co/Co ;WAP-Cre, Brca1
Co/Co ;MMTV-Cre, Brca1 Ko/Co ;WAP-Cre, or Brca1
Ko/Co ;MMTV-Cre, respectively. There were no signi®cant dierences between the four groups of mice, therefore for clarity, we designate these mice as Brca1
Co/Co ;MMTV-Cre. After following these mice (n=150) over a 2 year period, we found that only about 25% (n=35) of Brca1
Co/Co ;MMTV-Cre mice formed mammary tumors (Figure 1a) . The earliest tumors formed in these mice at 8 months of age, two of the animals had metastases to the lung, and the majority of the animals (76%) had a single mammary tumor (Figure 1b ).
We have also followed tumor initiation and progression in 56 Brca1
Co/Co ;MMTV-Cre;p53 +/7 mice. The mice had a dramatic increase in mammary tumor formation with over half of the animals having mammary tumors by 8 months of age ( Figure 1a) . By 15 months of age, virtually all of the Brca1 Co/Co ; MMTV-Cre;p53 +/7 mice had mammary tumors and most had lost their wt p53 allele (not shown). In contrast, no mammary tumors were observed in p53 +/7 mice although some of these mice developed other types of spontaneous tumors that were similar to tumors described previously (Brodie et al., 2001; Donehower et al., 1992; Harvey et al., 1993) . The decreased latency and increased number of tumors in the Brca1
Co/Co ;MMTV-Cre;p53 +/7 mice con®rms p53's role in Brca1-associated tumorigenesis. Metastasis was identi®ed in three Brca1
Co/Co ;MMTV-Cre;p53 +/7 mice. Of 50 mice analysed, the majority of mice (76%) developed one or two tumors and the remaining developed from three to eight tumors (Figure 1b) . Despite this acceleration, tumor formation in Brca1
Co/Co ;MMTV-Cre;p53 +/7 mice is still sporadic and stochastic, suggesting the involvement of additional factors in Brca1-associated tumorigenesis.
Histologic features of mammary tumors from Brca1 conditional knockout mice Next, we analysed the histologic features of Brca1 conditional knockout mammary tumors. Tumors generated in both Brca1 Co/Co ;MMTV-Cre and Brca1-Co/Co ;MMTV-Cre;p53 +/7 mice were similar in histology and were highly diverse and phenotypically ranged in sequence from atypical hyperplasia (Figure 2a Figure 2m ,n) were also observed. These ®ndings dier from other mouse mammary tumor models overexpressing speci®c oncogenes that often show consistent morphologic features (Cardi et al., 1991 and Figure 2o ). The absence of consistent morphologic features in Brca1 tumors, other than the abnormal appearing nuclei, high mitotic index and aggressiveness, suggests that the loss of Brca1 may lead to random genetic alterations giving Brca1 de®cient tumors their diverse histologic appearance.
ErbB2, c-Myc and Cyclin D1 are overexpressed in Brca1 conditional mammary tumors
The diverse histologic appearance of the mammary tumors formed in Brca1 de®cient mice led us to search for alterations in primary tumors. The genetic instability in Brca1 mutant cells could result in loss of heterozygosity (LOH) for genomic loci harboring tumor suppressor genes and/or ampli®cation of genomic regions containing oncogenes. Using a candidate gene approach, we asked whether the protein products, such as ErbB2 and c-Myc protooncogenes and Cyclin D1, encoded in these ampli®ed genomic regions were overexpressed in the mammary tumors from Brca1 conditional knockout mice. As shown in Figure 3 , ErbB2 and Cyclin D1 were overexpressed using immunohistochemistry (Figure 3b, c) . Western analysis of primary mammary tumors demonstrated that 81% (9/11) of the cases analysed overexpressed ErbB2 (Figures 3e and 4a ). Cyclin D1, cell cycle regulatory protein was overexpressed in all tumors at varying levels (Figures 3e and 4b ). In addition, most tumors showed increased c-Myc expression (Figures 3e and 4a ). These results suggested that genes commonly overexpressed in sporadic forms of breast cancer are also overexpressed in tumors generated in Brca1 conditional knockout mice.
Cell lines generated from mammary tumors
Next, we derived cell lines from Brca1 conditional knockout mammary tumors to see if they maintained the genetic changes. Our hypothesis is that if genetic changes observed in primary tumors are indeed required for tumor progression, then these genetic changes would be observed in cultured cells generated from the primary tumors. Cell lines were generated from tumors of the third mammary gland from mice at 9 (W525) and 11 (W780) months of age and from the fourth gland of an animal that was 1 year old (W0069). All animals were Brca1
Ko/Co ; WAP-Cre; p53 +/7 and had a single large mammary tumor of similar size. Histologically, the tumors were high-grade adenocarcinoma with signs of transdierentiation into squamous carcinomas (W525, Figure 2c ,g,h), ®bro-adenoma with strong stromal reaction (W0069, Figure  2i ), or sheets of adenocarcinoma cells with abnormal nuclei (W780, Figure 2f ). The cultured tumor cells grew as adherent monolayers with an epithelial appearance and formed visible tumors by 21 days after they were injected into NuJ mice (not shown), con®rming the malignant nature of these cells. The doubling times for cell lines W525, W0069 and W780 were 9.8, 11.2 and 10.6 h, respectively. For each cell line, 30 metaphase spreads from early passage (P6) were analysed ( Figure 3f ). All of the spreads were aneuploid having greater than the diploid number of chromosomes (diploid number=40). Most of the spreads also exhibited structural aberrations as observed in primary tumors (not shown). In addition, we have also found that these tumor cells displayed genetic alterations of p53 at DNA or protein levels (not shown). This is consistent with our ®ndings that p53 loss accelerates Brca1-associated tumorigenesis (Xu et al., 1999a ).
ErbB2, c-Myc and Cyclin D1 overexpression in Brca1 mammary tumor cell lines
The next question we wanted to address was whether oncogenes overexpressed in the primary tumors were also overexpressed in cell lines generated from the mammary tumors. As shown in Figure 4a , ErbB2 was not detectable in control tissues at lactation day 2 (L2), however the protein is expressed at low levels at pregnancy day 16 (P16). In the Brca1 mammary tumor cell lines, ErbB2 was overexpressed at levels similar to the primary tumors (Figures 4a and 3e) . During L2 and P16, c-Myc is not detectable however, the cell lines derived from Brca1 de®cient mice and Brca1 mammary tumors overexpressed the protein (Figure 4a) . Levels of Cyclin D1 were not detectable at L2 or P16 in normal tissues but overexpression of the protein was observed in the Brca1 cell lines (Figure 4b ). Because ErbB2, c-Myc and Cyclin D1 are overexpressed in the primary tumors and cell lines, this data would suggest that these genes are required for tumor maintenance.
Expression of p16, p21 and p27 in brca1 mammary tumors and cultured cells Cellular integrity is maintained by the various roles of Brca1 and p53 in cell cycle checkpoint control, apoptosis and genome stability. Progression through ;MMTV-Cre (T3, T4, T5, T6, T8, T9) and normal mouse mammary tissue from virgin (v), pregnancy day 12 (P12) and 16 (P16), lactation day 2 (L2) and 10 (L10) and involution day 2 (I2) and 10 (I10). (f) Graph demonstrating chromosome numbers found in Brca1 mammary tumor cell lines p16, p21 and p27, in normal mammary tissue, mammary tumors and cell lines. As shown in Figure  4d , using Western analysis, no detectable levels of p16 were found in the primary tumors or cell lines. In some of the tumors, we observed slightly elevated levels of p21 expression (Figure 4d ). This data may suggest that down regulation of p16 and slightly elevated p21 expression in Brca1 tumors may be correlated with the targeted disruption of Brca1 and may be independent of the triggered loss of p53. On the other hand, we found p27 protein levels were increased in all of the tumors and cell lines (Figure 4b,c) .
Expression of cyclins A, B1, E and Cdc2 in primary tumors and cultured cells
Tumor progression may involve increased proliferation and progression through the cell cycle. Therefore, we were interested in determining whether Brca1 de®cient tumors showed increased expression in other cyclins as observed with Cyclin D1 (Figures 3c,e and 4b) . Using Western blot analysis, we found that cyclins A, B1 and E were not detectable in asynchronized cultured cells (Figure 4b ). This would suggest that in our culture system, these proteins are not induced in response to loss of Brca1. In primary tumors, we also found no detectable dierences in protein expression of cyclins A, B1 and E in addition to Cdc2 in mammary tumors compared to protein expression observed in control mammary tissue at P16 and L2 (Figure 4c,d ). This data suggests that Cyclin D1, whose increased expression is associated with increased proliferation, is the primary cyclin involved in Brca1-associated tumorigenesis. Of note, we observed that all primary tumors and cell lines expressed Cdc2. The signi®cance of this event is not clear and requires further investigation.
Brca1 mammary tumor cell lines are sensitive to Doxorubicin/Adriamycin and g-irradiation
Cellular responses to chemotherapeutic agents are often associated with changes in hormones and proteins responsible for cell cycle checkpoints and apoptosis (Darzynkiewicz, 1995; Fisher, 1994) . It has been reported that a high percentage of BRCA1-associated breast cancer is ERa negative (Alberg and Helzlsouer, 1997; Brody and Biesecker, 1998; Paterson, 1998) . Therefore, we decided to determine the receptor status of primary tumors and cell lines generated from mammary tumors. Using Western blots, we found that majority of primary tumors had no detectable levels of ERa (Figure 4c ), suggesting that these tumors escaped estrogen regulation. Consistently, all three Brca1 cell lines, which were derived from ERa negative tumors, did not respond to Tamoxifen treatment (not shown). p53 is one of the genes known to mediate responses to cellular stress. As these Brca1 tumor derived cell lines lost p53, we were interested in determining their response to chemotherapeutic agents. Our data indicated that Doxorubicin, a therapeutic agent, which leads to double strand breaks by inhibition of topoisomerase II (Tewey et al., 1984) was able to kill these cells eectively at doses of 0.5 mg/ml or higher (Figure 5a ). Of note, we found that all of these Brca1-mutant cancer cells were more sensitive to g-irradiation than mammary tumor cells isolated from mice bearing MMTV-c-neu (this study) or MMTV-ras transgenes (Hundley et al., 1997) at low radiation doses ( Figure  5b ). At doses of 5 Gy, over half of the Brca1 tumor cell lines had died while over 90% ras and c-neu tumor cells were still alive under identical treatment and culture conditions. However, 20 Gy of g-irradiation was able to kill the majority of cells from all cell lines (Figure 5b ). These results would suggest that large BRCA1-de®cient tumors may not respond to Tamoxifen treatment but may be eectively treated with the use of Doxorubicin or g-irradiation.
Discussion
Numerous investigations have revealed that Brca1 has essential functional roles in multiple biologic pathways (reviewed in Deng and Brodie, 2000) . A number of Brca1 knockout mouse models have been generated that die during embryonic development and primarily exhibit developmental delay and cellular proliferation defects (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) . This leads to a question of how can BRCA1 repress breast tumor formation if loss of gene function results in proliferation defects. In an attempt to answer this question, our laboratory, using a Cre-loxP approach, generated a mouse model for Brca1 related mammary tumorigenesis which allowed Cre-mediated recombination of Brca1 in mammary epithelial cells (Xu et al., 1999a) . The mice develop mammary tumors at a low frequency after long latency, suggesting that multiple factors may be involved in Brca1 related tumorigenesis. After introducing a targeted mutation of p53 into the Brca1 conditional knockout mice, we demonstrated that p53 plays a major role in Brca1-associated mammary tumorigenesis. However, other genetic events that might also be involved in tumor initiation and progression have yet to be determined. In this study, we have investigated roles of a number of proteins, whose expression is known to eect sporadic breast cancer formation. Some of these proteins are also known to interact with BRCA1 directly or indirectly (Deng and Brodie, 2000) . Our analysis on primary tumors and cell lines demonstrated that the majority carries p53 alterations at the DNA and protein levels (Xu et al., 1999a (Xu et al., , b, 2001 and this study) and is ERa negative. In addition, we found the overexpression of ErbB2, c-Myc, Cyclin D1, Cdc2 and p27, and the loss of p16 expression as additional genetic/molecular changes that are associated with tumor initiation and progression, revealing a quite complex pattern of tumor formation in Brca1-associated tumorigenesis.
Previous investigations revealed that ErbB2 overexpression is one of the most frequent genetic alterations found in sporadic breast cancer (reviewed in Menard et al., 2000) . In BRCA1-associated breast cancer, immunohistochemical detection of ErbB2 overexpression is usually found in less than 25% of cases (Johannsson et al., 1997; Robson et al., 1998) . In our study, immunohistochemical and Western analysis on primary tumors and cell lines from Brca1 conditional knockout mice demonstrated ErbB2 overexpression. Our study also showed that mammary tumors and their cell lines expressed Cyclin D1 at high levels. In humans, expression of Cyclin D1, a protein overexpressed in 20% of sporadic breast cancers, is often used as a prognostic indicator for response to endocrine treatment (Barnes and Gillett, 1998) . Half of the BRCA1-associated breast cancers were positive for Cyclin D1 expression (Robson et al., 1998) . The same study also showed that the majority of the tumors were p27 positive. In our study we found that Cyclin D1 and p27 were overexpressed in all tumors at varying levels. We also showed that c-Myc, a transcription factor that is upregulated/overexpressed in a variety of sporadic breast cancers (Bieche and Lidereau, 1995) , was expressed at higher levels in most Brca1 mammary tumors. These observations indicate that the changes found in sporadic forms of human breast cancer also occur in Brca1-associated tumorigenesis.
For some genes, such as c-Myc and ErbB2, overexpression of either in the mouse mammary epithelium alone is sucient to induce tumor formation (Guy et al., 1992; Hutchinson and Muller, 2000; Leder et al., 1986; Mueller et al., 1997) . Then, why do these changes have to occur in Brca1-associated tumors together and what are their roles? To search for answers, we analysed the Brca1 tumors and found them to be histologically highly diverse (Figure 2 ). These variable phenotypic features are unique to Brca1 and diers from previous breast cancer models, which normally have distinct morphologies because dierent oncogenes activated in these tumors exert sucient in¯uence on the histologic pattern of the tumors (Cardi et al., 1991 (Cardi et al., , 2000 . A speci®c example is tumor sample W525, which expresses ErbB2 (Figure 3b ) and exhibits diverse morphologies (Figure 2c ,g,h) that are distinct from tumors of transgenic mice where ErbB2 is a sole driving force for tumor initiation (Figure 2o ). This observation would suggest that genetic changes associated with the loss of Brca1 are random and may involve multiple cellular pathways. In other words, we would like to suggest that BRCA1-associated tumorigenesis is a consequence of a combination of multiple genetic events/factors and no speci®c genetic change has a large in¯uence on the histologic features of Brca1 tumors.
Lastly, we asked whether Brca1-associated breast tumors, with their random genetic changes, respond to common therapeutic agents. Despite the fact that multiple factors and/or pathways were found to be dysregulated in the tumors, we showed that cell lines generated from the tumors were still sensitive to Doxorubicin. Interestingly, our data revealed that Brca1 tumor cells were signi®cantly more sensitive to g-irradiation than tumor cells driven by Ras or c-Neu oncogenes. Although, this is an in-vitro ®nding that requires further investigation, it is consistent with a role of BRCA1 in DNA damage repair as shown by a number of recent studies (Gowen et al., 1998; Moynahan et al., 1999) . Nonetheless, our data suggest that Brca1 tumors, with their long latency, diverse histopathological features and multiple genetic changes, are readily treatable using commonly available chemotherapeutic agents, especially radiation therapies.
Materials and methods
Mice, genotyping and tumorigenesis
Brca1 conditional knockout mice (Xu et al., 1999a) in p53 wt or heterozygous (Donehower et al., 1992) background were maintained in a pathogen free facility and were genotyped as described. The Brca1 and p53 status of the mice, mammary tumors and cells were determined by PCR or Southern blotting using Brca1 and p53 probes previously described (Xu et al., 1999a) . Brie¯y, 10 mg of genomic DNA from each sample was digested overnight with EcoRV for Brca1 analysis or EcoRI for p53 analysis. DNA was transferred to nitrocellulose, dried, hybridized with probes and exposed on ®lm. Animals in all experiment groups were checked weekly after birth and the ®rst day tumors were noticed the animals were recorded as developing tumors. Complete autopsies were performed and both gross and microscopic evaluations were performed.
Histology and antibody staining
For histology, tissues were ®xed in the 10% formalin, blocked in paran, sectioned, stained with hematoxylin and eosin, and examined by light microscopy. Cyclin D1 and ErbB2 antibodies were purchased from Santa Cruz Biotechnology. K14 was purchased from Covance Inc. Detection of primary antibodies was performed using the ZYMED Histomouse TM SP Kit according to manufacturer's instructions.
Generation of tumor cell lines and chromosome analysis of tumor cells
Portions of mammary tumors were brie¯y washed in PBS and minced in MEBM/MEGM media (Clonetics) containing 10 mg/ml of bacterial collagenase type III (Gibco). After overnight digestion, released cells and ®nely minced tissues were pelleted, washed in PBS and cultured in MEBM/ MEGM media. Cultures were monitored for epithelial cell growth and the media changed every 3 days. When ®broblastic cells died and adherent epithelial cells remained, the cultures were trypsinized and passed in DMEM medium supplemented with 5% FBS. Chromosomes were prepared as described by Shen et al. (1998) with the following modi®cations. At passage 6 (P6), the tumor cell lines were treated for 1 h with Colcemid (Sigma). The media was then removed and the cells were trypsinized and resuspended gently in 0.56% KCl and incubated at 378C for 5 min. The cells were then ®xed in a 3 : 1 mixture of methanol:acetic acid and the cells were then processed as described.
Northern and Western blotting
Northern blots were performed using 20 mg of total RNA isolated from normal mammary, primary tumors and cultured cell lines as previously described (Xu et al., 1999a) . Brie¯y, subcon¯uent cultures were washed with PBS and scraped from plates with a rubber policeman. The cells were lysed in RNA STAT60 TM (Tel-Test, inc.) and frozen at 7708C until used. RNA from each sample was electrophoresed on the 1% agarose gel and transferred to a Nitrocellulose membrane. The nitrocellulose was hybridized with a 32 P labeled probe speci®c for Brca1 and p53 (Xu et al., 1999a) . Western analysis was performed using standard procedures. Antibodies against p53, p21, p18, p16, Cyclin D1, and ERa were purchased Oncogene Multiple genetic changes in Brca1 mammary tumors SG Brodie et al from Santa Cruz and cyclins A, B1, E were purchased from Novocastra.
g-Irradiation and chemosensitivity assays
Conditions for cultured irradiation experiments were performed as described (Shen et al., 1998) . Brie¯y, subcon¯uent cultured cells at passage 30 were subjected to 0 to 20 Gy of girradiation at a dose of 97 rads/min. Cells were incubated for 7 days and counted. Analysis was performed as compared to the percentage of viable cells after irradiation compared to unirradiated cells. For chemosensitivity assays, cells at passage 22 were subjected to sensitivity testing using Doxorubicin, Tamoxifen and 17b-estradiol. Stock solutions of Tamoxifen and 17b-estradiol were prepared in ethanol and subsequent dilutions were made in growth medium such that all drug concentrations were exposed to a ®nal concentration of less than 0.01% ethanol. Cells were exposed to Tamoxifen at concentrations of 10 75 , 10 76 , 10
77
, 10 78 or 10 79 M. Cells were exposed to 17 b-estradiol (10 79 M) or 0.01% ethanol in parallel. Doxorubicin stock solutions were prepared in HBSS and drug sensitivity was determined at 0.01, 0.1, 0.5, 1.0, and 5 mg/ml.
